<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131152">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01949077</url>
  </required_header>
  <id_info>
    <org_study_id>11-2124</org_study_id>
    <nct_id>NCT01949077</nct_id>
  </id_info>
  <brief_title>Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.</brief_title>
  <official_title>Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine differences in levels of serum chemokines from
      patients undergoing treatment with Boceprevir.  The aim is to determine if non-responders
      have significantly different levels of chemokines than responders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing standard of care at the UNC Liver Center are consented for collection of
      an additional serum sample under the UNC Liver Center serum and tissue bank study.  These
      samples will be used to analyze differences in serum chemokines across responders and
      non-responders.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Level (ng/mL) of serum chemokines.</measure>
    <time_frame>Baseline: &lt;=6 months prior to start of treatment and Post-treatment: &lt;=6-months after the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare levels of serum chemokines across Boceprevir responders (SVR) and non-responders for both Baseline (&lt;=6-months pre-treatment) and Post-treatment (&lt;=6-months post-treatment).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Sustained virological response</arm_group_label>
    <description>Patients who achieve sustained virological response (SVR) are defined as undetectable HCV RNA in serum obtained 12 weeks or beyond the end of antiviral therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-responders</arm_group_label>
    <description>Non-responders are defined as patients who have not achieved virological milestones during therapy or who have relapsed with detectable HCV RNA in serum after cessation of treatment.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and tissue collected through the UNC Liver Center serum and tissue bank.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female adult patients: Aged 18 and older with chronic HCV treated with triple
        therapy (including Boceprevir).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients (age 18 or older) treated with an antiviral Hepatitis C treatment
             regimen that includes Boceprevir.

        Exclusion Criteria:

          -  Inability to provide informed consent for a serum sample enrolled in the University
             of North Carolina Liver Center serum bank.

          -  No pre and post serum sample available within 6 months of the treatment period.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W Fried, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina Liver Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 19, 2013</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Michael Fried, MD</investigator_full_name>
    <investigator_title>Professor of Medicine, Director, UNC Liver Center</investigator_title>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Observational study</keyword>
  <keyword>Biomarkers of treatment response</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
